Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial-Reference-Cited by-同舟云学术

Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial

Published:2022-06-08 Issue:10 Volume:41 Page:3005-3016
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Li Jia^ORCID,Xue Zhixin^ORCID,Wu Zhenbiao^ORCID,Bi Liqi^ORCID,Liu Huaxiang^ORCID,Wu Lijun^ORCID,Liu Shengyun^ORCID,Huang Xiangyang^ORCID,Wang Yong^ORCID,Zhang Yan^ORCID,Qi Wufang^ORCID,He Lan^ORCID,Dai Lie^ORCID,Sun Lingyun^ORCID,Li Xiaomei^ORCID,Shuai Zongwen^ORCID,Zhao Yi^ORCID,Wang Yanyan^ORCID,Xu Jian^ORCID,Zhang Hao^ORCID,Yu Hao^ORCID,Chen Xiaoxiang^ORCID,Bao Chunde^ORCID

Funder

Chia Tai Tianqing Pharmaceutical Group Co., Ltd, China

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s10067-022-06199-8.pdf

Reference33 articles.

1. Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73–84. https://doi.org/10.1016/S0140-6736(16)31591-4

2. Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563–2574. https://doi.org/10.1056/NEJMra1406182

3. Jieruo G, Xie Y, Kehu Y, Qing L, Yi Z, Cibo H et al (2020) Practice guideline for patients with ankylosing spondylitis/spondyloarthritis. Zhonghua Nei Ke Za Zhi 59(7):511–518. https://doi.org/10.3760/cma.j.cn112138-20200505-00448

4. Liudan T, Rai JC, Cao S, Lin Z, Hu Z, Gu J (2014) Costs and work limitation of patients with ankylosing spondylitis in China. Clin Exp Rheumatol 32(5):661–666

5. Ritchlin C, Adamopoulos IE (2021) Axial spondyloarthritis: new advances in diagnosis and management. BMJ 372:m4447. https://doi.org/10.1136/bmj.m4447

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Clinical Benefit, Cost and Uptake of Biosimilars Versus Reference Biologics in Immune-Mediated Inflammatory Diseases in China;2024